秋水仙碱对移植后毛细血管渗漏综合征和肾衰竭的显著效果
本文报告2例儿童移植后(心脏和骨髓)发生危及生命的毛细血管渗漏综合征伴肾衰竭,对其它治疗均无反应,仅靠支持治疗维持。使用秋水仙碱后迅速出现利尿和临床恢复,数小时内停止肾脏替代治疗;因一过性白细胞减少暂停秋水仙碱后渗漏和肾衰竭复发,重新引入后恢复。随访6个月肾功能良好,无渗漏复发。
要点
- 移植后毛细血管渗漏综合征伴肾衰竭的儿童,秋水仙碱可能快速改善利尿和临床状态。
- 暂停秋水仙碱后渗漏和肾衰竭复发,重新用药后恢复,提示其治疗作用。
- 与免疫抑制剂联用需注意一过性白细胞减少,减量使用下未观察到其他不良事件。
核心结论
- 秋水仙碱在2例移植后毛细血管渗漏综合征伴肾衰竭的危重儿童中显示出显著快速的治疗效果,提示其可作为此类危重病例的抢救工具。
研究设计与样本
- 本文为病例报告,报告了2例儿童移植后(心脏和骨髓)发生毛细血管渗漏综合征伴肾衰竭的病例。
主要发现
- 2例患儿对其它治疗均无反应,仅靠支持治疗维持。
- 使用秋水仙碱后利尿和临床状况迅速改善,数小时内停止肾脏替代治疗。
- 因一过性白细胞减少暂停秋水仙碱后,渗漏和肾衰竭复发,重新引入后恢复。
- 随访6个月,2例患儿肾功能良好,无渗漏复发。
关键数值与推荐
- 使用减量秋水仙碱与免疫抑制剂联用时,除一过性白细胞减少外未观察到其他不良事件。
临床怎么用
- 对于移植后发生毛细血管渗漏综合征伴肾衰竭且对常规治疗无反应的危重儿童,可考虑秋水仙碱作为抢救治疗。
- 使用秋水仙碱时需监测白细胞减少,尤其与霉酚酸酯等免疫抑制剂联用时。
局限性
- 本文仅为2例病例报告,证据级别有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Capillary leak syndrome is a critical condition occasionally occurring posttransplant and is characterized by acute endothelial hyperpermeability leading to systemic protein-rich fluid extravasation and consequent hypovolemia, hypoperfusion, and acute kidney injury. Treatment is merely supportive and is based on osmotic drugs, diuretics, continuous renal replacement therapy, and surgical drainage. However, removal of the underlying inflammatory cause is mandatory to achieve stable resolution. Herein, we report the first successful treatment with colchicine in 2 life-threatening pediatric cases of capillary leak syndrome with renal failure occurring after transplant (heart and bone marrow) and unresponsive to any other line of therapy. Both cases were only palliated by supportive therapy and revealed an impressively rapid response to colchicine both in terms of diuresis and clinical condition recovery, allowing for the cessation of renal replacement therapy in a few hours. In both patients, colchicine was temporarily discontinued for transient leukopenia (attributed to an additive effect with mycophenolate mofetil), resulting in extravasation, and renal failure recurrence was restored only after colchicine reintroduction. Although the association of colchicine with an immunosuppressive drug was formerly contraindicated, no other adverse events were noted when using a minimized dose. Both patients are now maintaining a good renal function without recurrence of extravasation after 6 months of follow-up. In conclusion, this strikingly positive experience forces physicians to consider this old and cost-effective drug as a new, powerful rescue tool in such critical cases.
引用
- Cocchi E, Chiale F, Gianoglio B, et al. Colchicine: An Impressive Effect on Posttransplant Capillary Leak Syndrome and Renal Failure. Pediatrics. 2019. PMID: 31000685. doi:10.1542/peds.2018-2820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。